Alkermes plc (NASDAQ:ALKS) is reporting second quarter financial results on Wednesday 29th July 2020, before market open.
According to analysts surveyed by Thomson Reuters, ALKS is expected to report 2Q20 loss of $ 0.01 per share from revenue of $ 232.75 million.
For the full year, analysts anticipate top line of $ 983.04 million, while looking forward to loss of $ 0.01 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,030.00 million ~ $ 1,080.00 million, where as bottomline are predicted in a range of $ 0.25 ~ $ 0.43 per share
Click Here For More Historical Outlooks Of Alkermes plc
Previous Quarter Performance
Alkermes plc unveiled income for the first quarter of $ 0.01 per share, from the revenue of $ 246.22 million. The quarterly earnings escalated 24.66 percent while revenues compared with the same quarter last year.
The consensus estimates are loss of $ 0.06 per share from $ 228.23 million in revenue. The bottom line results beat street analysts by $ 0.07 or 116.67 percent, at the same time, top line results outshined analysts by $ 17.99 million or 7.88 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Alkermes plc
Stock Performance
According to the previous trading day, closing price of ALKS was $ 20.18, representing a 68.45 % increase from the 52 week low of $ 11.98 and a 14.13 % decrease over the 52 week high of $ 23.50.
The company has a market capital of $ 3.20 billion and is part of the Healthcare sector and Drug Delivery industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ALKS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Alkermes plc will be hosting a conference call at 8:00 AM eastern time on 29th July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.alkermes.com
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The companys marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders.
